Libby, Peter
Buring, Julie E.
Badimon, Lina
Hansson, Göran K.
Deanfield, John
Bittencourt, Márcio Sommer
Tokgözoğlu, Lale
Lewis, Eldrin F.
Article History
Accepted: 4 July 2019
First Online: 16 August 2019
Competing interests
: P.L. is an unpaid consultant to, or involved in clinical trials for, Amgen, AstraZeneca, Esperion Therapeutics, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Novartis, Pfizer, Sanofi-Regeneron and XBiotech, Inc. P.L. is a member of scientific advisory boards for Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, IFM, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune and Novartis. P.L.’s laboratory has received research funding in the last 2 years from Novartis. L.B. has performed lectures and advisory board work in 2017 for Sanofi, Amgen and Astrazeneca. L.B. receives research grant support from AstraZeneca and research funding and grants from Fondo de Investigaciones Sanitarias (FIS), Plan Nacional-Retos MINECO and the EU. G.K.H. is the inventor of patents regarding immune therapy in atherosclerosis. G.K.H. is also the recipient of grants for research on immune mechanisms in atherosclerosis from the Swedish Research Council, the Swedish Heart-Lung Foundation and the EU. J.D. has received CME honoraria and/or consulting fees from Amgen, Boehringer Ingelheim, Merck, Pfizer, Aegerion, Novartis, Sanofi, Takeda, Novo Nordisk and Bayer. J.D. is a member of a Study Steering Committee for Novo Nordisk and has received research grants from the British Heart Foundation, MRC(UK), NIHR, PHE, MSD, Pfizer, Aegerion, Colgate and Roche. M.S.B. has received research support funding from Sanofi and consulting fees from Boston Scientific. L.T. is a member of the scientific advisory boards for Merck, Abbott, Amgen, Sanofi and Daichi Sankyo. L.T. also performed lectures for Abbott, Astra, Actelion, Merck, Servier, Recordati, Mylan, Amgen, Novartis, Sanofi, Pfizer, Bayer, Novo Nordisk and Sanovel. E.F.L. reports institutional research grant and consulting from Novartis, and institutional research grants from Amgen and Sanofi. J.E.B. declares no competing interests.